In the Claims:

A complete listing of claims 1-19 with status identifier follows.

Claim 1 (Currently Amended) A method of treating a susceptible cancer in a human or animal subject in need thereof, comprising administering to said subject an effective amount of a compound of formula (I):



(I)

or a salt or solvate thereof;

wherein X is N or CH;

Y is a group $W(CH_2)$, $(CH_2)W$, or W, in which W is O, $S(O)_m$ wherein m is 0, 1 or 2, or NR^a wherein R^a is hydrogen or a C_{1-8} alkyl group;

R^1 is ~~represents~~ a 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from the group N, O or $S(O)_m$, wherein m is as defined above, with the provisos that the ring does not have two adjacent O or $S(O)_m$ atoms and that where the ring has only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring, R^1 being optionally substituted by one or more R^3 groups;

each R^3 is independently selected from the group consisting of amino, hydrogen, halogen, hydroxy, nitro, carboxy, formyl, cyano, trifluoromethyl,

trifluoromethoxy, carbamoyl, ureido, guanidino, C_{1-8} alkyl, C_{1-8} alkoxy, C_{3-8} cycloalkoxyl, C_{4-8} alkylcycloalkoxy, C_{1-8} alkylcarbonyl, C_{1-8} alkoxycarbonyl, N-C_{1-4} alkylcarbamoyl, N,N-di-[C_{1-4} alkyl]carbamoyl, hydroxyamino, C_{1-4} alkoxyamino, C_{2-4} alkanoyloxyamino, C_{1-4} alkylamino, di[C_{1-4} alkyl]amino, di-[C_{1-4} alkyl]amino-C_{1-4} alkylene-(C_{1-4} alkyl)amino, C_{1-4} alkylamino- C_{1-4} alkylene-(C_{1-4} alkyl)amino, hydroxy-C_{1-4} alkylene-(C_{1-4} alkyl)amino, phenyl, phenoxy, 4-pyridon-1-yl, pyrrolidin-1-yl, imidazol-1-yl, piperidino, morpholino, thiomorpholino, thiomorpholino-1-oxide, thiomorpholino-1,1-dioxide, piperazin-1-yl, 4-C_{1-4} alkylpiperazin-1-yl, dioxolanyl, C_{1-8} alkylthio, arylthio, C_{1-4} alkylsulphinyl, C_{1-4} alkylsulphonyl, arylsulphonyl, arylsulphinyl, halogeno-C_{1-4} alkyl, hydroxy-C_{1-4} alkyl, C_{2-4} alkanoyloxy-C_{1-4} alkyl, C_{1-4} alkoxy-C_{1-4} alkyl, carboxy-C_{1-4} alkyl, formyl-C_{1-4} alkyl, C_{1-4} alkoxycarbonyl-C_{1-4}-alkyl, carbamoyl-C_{1-4} alkyl, N-C_{1-4} alkylcarbamoyl-C_{1-4}alkyl, N,N-di-[C_{1-4} alkyl]carbamoyl-C_{1-4}alkyl, amino-C_{1-4} alkyl, C_{1-4} alkylamino-C_{1-4} alkyl, di-[C_{1-4} alkyl]amino-C_{1-4} alkyl, phenyl-C_{1-4} alkyl, 4-pyridon-1-yl-C_{1-4} alkyl, pyrrolidin-1-yl-C_{1-4} alkyl, imidazol-1-yl-C_{1-4} alkyl, piperidino-C_{1-4} alkyl, morpholino-C_{1-4} alkyl, thiomorpholino-C_{1-4} alkyl, thiomorpholino-1-oxide-C_{1-4}alkyl, thiomorpholino-1,1-dioxide-C_{1-4}alkyl, piperazin-1-yl-C_{1-4}alkyl, 4-C_{1-4} alkylpiperazin-1-yl-C_{1-4} alkyl, hydroxy-C_{2-4} alkoxy-C_{1-4} alkyl, C_{1-4} alkoxy-C_{2-4} alkoxy-C_{1-4} alkyl, hydroxy-C_{2-4} alkylamino-C_{1-4} alkyl, C_{1-4} alkoxy-C_{2-4} alkylamino-C_{1-4} alkyl, C_{1-4} alkylthio-C_{1-4} alkyl, C_{1-4} alkylsulphinyl-C_{1-4} alkyl, C_{1-4} alkylsulphonyl-C_{1-4} alkyl, hydroxy-C_{2-4} alkylthio-C_{1-4} alkyl, C_{1-4} alkoxy-C_{2-4} alkylthio-C_{1-4} alkyl, phenoxy-C_{1-4} alkyl, anilino-C_{1-4} alkyl, phenylthio-C_{1-4} alkyl, cyano-C_{1-4} alkyl, halogeno-C_{2-4} alkoxy, hydroxy-C_{2-4} alkoxy, C_{2-4} alkanoyloxy-C_{2-4} alkoxy, C_{1-4} alkoxy-C_{2-4} alkoxy, carboxy-C_{1-4} alkoxy, formyl-

C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl-C_{1-4} alkoxy, carbamoyl-C_{1-4} alkoxy, N-C_{1-4} alkylcarbamoyl-C_{1-4} alkoxy, N,N-di-[C_{1-4} alkyl]carbamoyl-C_{1-4} alkoxy, amino-C_{2-4} alkoxy, C_{1-4} alkylamino-C_{2-4} alkoxy, di-[C_{1-4} alkyl]amino-C_{2-4} alkoxy, di-[C_{1-4} alkyl-C_{2-4} alkoxy]amino-C_{2-4} alkoxy, C_{2-4} alkanoyloxy, hydroxy-C_{2-4} alkanoyloxy, C_{1-4}alkoxy-C_{2-4} alkanoyloxy, phenyl-C_{1-4} alkoxy, phenoxy-C_{2-4} alkoxy, anilino-C_{2-4} alkoxy, phenylthio-C_{2-4} alkoxy, 4-pyridon-1-yl-C_{2-4} alkoxy, piperidino-C_{2-4} alkoxy, morpholino-C_{2-4} alkoxy, thiomorpholino-C_{2-4} alkoxy, thiomorpholino-1-oxide-C_{2-4} alkoxy, thiomorpholino-1,1-dioxide-C_{2-4} alkoxy, piperazin-1-yl-C_{2-4} alkoxy, 4-C_{1-4} alkylpiperazin-1-yl-C_{2-4} alkoxy, pyrrolidin-1-yl-C_{2-4} alkoxy, imidazol-1-yl-C_{2-4} alkoxy, halogeno-C_{2-4} alkylamino, hydroxy-C_{2-4} alkylamino, C_{2-4} alkanoyloxy-C_{2-4} alkylamino, C_{1-4} alkoxy-C_{2-4} alkylamino, carboxy-C_{1-4} alkylamino, C_{1-4} alkoxycarbonyl-C_{1-4} alkylamino, carbamoyl-C_{1-4} alkylamino, N-C_{1-4} alkylcarbamoyl-C_{1-4} alkylamino, N,N-di-[C_{1-4} alkyl]carbamoyl-C_{1-4} alkylamino, amino-C_{2-4} alkylamino, C_{1-4} alkylamino-C_{2-4} alkylamino, di-[C_{1-4}alkyl]amino-C_{2-4} alkylamino, phenyl-C_{1-4} alkylamino, phenoxy-C_{2-4} alkylamino, anilino-C_{2-4} alkylamino, 4-pyridon-1-yl- C_{2-4} alkylamino, pyrrolidin-1-yl-C_{2-4} alkylamino, imidazol-1-yl-C_{2-4} alkylamino, piperidino-C_{2-4} alkylamino, morpholino-C_{2-4} alkylamino, thiomorpholino-C_{2-4} alkylamino, thiomorpholino-1-oxide-C_{2-4} alkylamino, thiomorpholino-1,1-dioxide-C_{2-4} alkylamino, piperazin-1-yl-C_{2-4}alkylamino, 4-(C_{1-4}alkyl)piperazin-1-yl-C_{2-4}alkylamino, phenylthio-C_{2-4} alkylamino, C_{2-4} alkanoylamino, C_{1-4} alkoxycarbonylamino, C_{1-4} alkylsulphonylamino, C_{1-4} alkylsulphinylamino, benzamido, benzenesulphonamido, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, halogeno-C_{2-4} alkanoylamino, hydroxy-C_{2-4} alkanoylamino, hydroxy-C_{2-4} alkanoyl-(C_{1-4} alkyl)-amino, C_{1-4} alkoxy-C_{2-4} alkanoylamino,

carboxy-C_{2-4} alkanoylamino, C_{1-4} alkoxycarbonyl-C_{2-4} alkanoylamino, carbamoyl-C_{2-4} alkanoylamino, N-C_{1-4} alkylcarbamoyl-C_{2-4} alkanoylamino, N,N-di-[C_{1-4} alkyl]carbamoyl-C_{2-4} alkanoylamino, amino-C_{2-4} alkanoylamino, C_{1-4} alkylamino-C_{2-4} alkanoylamino and ~~or~~ di-[C_{1-4} alkyl]amino-C_{2-4} alkanoylamino; and wherein said benzamido or benzenesulphonamido substituent or any anilino, phenoxy or phenyl group on a R^3 substituent ~~may~~ optionally has ~~have~~ one or two halogeno, C_{1-4} alkyl or C_{1-4} alkoxy substituents; and wherein any substituent having a heterocyclic ring ~~may~~ optionally has ~~have~~ one or two halogeno, C_{1-4} alkyl or C_{1-4} alkoxy substituents on said ring; and wherein any substituent having a heterocyclic ring ~~may~~ optionally has ~~have~~ one or two oxo or thioxo substituents on said ring;

or R^3 is selected from the group consisting of ~~represents a group selected from~~ M^1-M^2-M^3-M^4, M^1-M^5 and ~~or~~ M^1-M^2-$M^{3'}$-M^6

wherein

M^1 is ~~represents~~ a C_{1-4} alkyl group, wherein optionally a CH_2 group is replaced by a CO group;

M^2 is ~~represents~~ NR^{12} or $CR^{12}R^{13}$, in which R^{12} and R^{13} each independently are ~~represent~~ H or C_{1-4} alkyl;

M^3 is ~~represents~~ a C_{1-4} alkyl group;

$M^{3'}$ is ~~represents~~ a C_{1-4} alkyl group or is absent;

M^4 is selected from the group consisting of ~~represents~~ CN, $NR^{12}S(O)_mR^{13}$, $S(O)_mNR^{14}R^{15}$, $CONR^{14}R^{15}$, $S(O)_mR^{13}$ and ~~or~~ CO_2R^{13}, in which R^{12}, R^{13} and m are as defined above and R^{14} and R^{15} each independently are ~~represent~~ H or C_{1-4} alkyl, or R^{14} and R^{15} together with the nitrogen atom to which they are attached form a 5-or 6-membered ring optionally containing 1 or 2 additional heteroatoms selected from N, O or $S(O)_m$ in which ring any nitrogen atom present is ~~may~~

optionally ~~be~~ substituted with a C_{1-4} alkyl group, and which ring ~~may~~ optionally has ~~have~~ one or two oxo or thioxo substituents;

M^5 is ~~represents~~ the group $NR^{14}R^{15}$, wherein R^{14} and R^{15} are as defined above, or

M^5 is ~~represents~~ the group



in which t is ~~represents~~ 2 to 4 and R^{16} is ~~represents~~ OH, OC_{1-4} alkyl or $NR^{14}R^{15}$; and

M^6 is selected from the group consisting of ~~represents~~ a C_{3-6} cycloalkyl group, the group $NR^{14}R^{15}$, wherein R^{14} and R^{15} are as defined above, and ~~or~~ a 5- or 6-membered heterocyclic ring system containing 1 to 4 heteroatoms selected from N, O or S;

and p is 0 to 3; or when p is 2 or 3, two adjacent R^3 groups together form an optionally substituted methylenedioxy or ethylenedioxy group;

R^2 is selected from the group consisting of hydrogen, halogen, trifluoromethyl, C_{1-4} alkyl and C_{1-4} alkoxy;

U is ~~represents~~ phenyl or a 5 to 10-membered mono or bicyclic ring system in which one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and $S(O)_m$, wherein m is 0,1 or 2, and wherein U is substituted by at least one independently selected R^6 group and U is optionally substituted by at least one independently selected R^4 group;

each R^4 is independently selected from the group consisting of hydrogen, hydroxy, halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylamino, di-[C_{1-4} alkyl]amino, C_{1-4} alkylthio, C_{1-4} alkylsulphinyl, C_{1-4} alkylsulphonyl, C_{1-4} alkylcarbonyl, C_{1-4} alkylcarbamoyl, di-[C_{1-4} alkyl] carbamoyl, carbamyl, C_{1-4} alkoxycarbonyl, cyano, nitro and ~~or~~ trifluoromethyl;

each R^6 is independently a group ZR^7 wherein Z is joined to R^7 through a $(CH_2)p$ group in which p is 0, 1 or 2 and Z is selected from a group consisting of ~~represents a group~~ $V(CH_2)$, $V(CF_2)$, $(CH_2)V$, $(CF_2)V$, V(CRR'), V(CHR) and ~~or~~ V where R and R' are each C_{1-4} alkyl and in which V is a hydrocarbyl group containing 0,1 or 2 carbon atoms, carbonyl, dicarbonyl, CH(OH), CH(CN), sulphonamide, amide, O, $S(O)_m$ or NR^b where R^b is hydrogen or R^b is C_{1-4} alkyl; and R^7 is an optionally substituted C_{3-6} cycloalkyl; or an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety;
or R^6 is a group ZR^7 in which Z is NR^b, and NR^b and R^7 together form an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety.

Claim 2 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein the susceptible cancer is a susceptible breast cancer.

Claim 3 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein the susceptible cancer is a susceptible non-small cell lung cancer.

Claim 4 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein the susceptible cancer is a susceptible ovarian cancer.

Claim 5 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein the susceptible cancer is a susceptible stomach cancer.

Claim 6 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein the susceptible cancer is a susceptible pancreatic cancer.

Claim 7 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein the susceptible cancer is a susceptible head and neck cancer.

Claim 8 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein the susceptible cancer is a susceptible cancer in which there is ~~characterized by~~ expression or over-expression of EGFR.

Claim 9 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein the susceptible cancer is a susceptible cancer in which there is ~~characterized by~~ expression or over-expression of erbB-2.

Claim 10 (Currently Amended): The A method as claimed in claim 1, wherein the susceptible cancer is a susceptible cancer in which there is ~~characterized by~~ expression or over-expression of EGFR and erbB-2.

Claim 11 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein X is N.

Claim 12 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein Y is NR^b, $NR^b(CH_2)$, or $(CH_2)NR^b$~~, preferably Y is NR^b and R^b is preferably hydrogen or methyl~~.

Claim 13 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein R^1 is a 5- or 6-membered heterocyclic ring as defined in claim 1 substituted with

an R^3 group selected from the group consisting of M^1-M^2-M^3-M^4, M^1-M^5 and ~~or~~ M^1-M^2-$M^{3'}$-M^6 as defined in claim 1 ~~or claim 2~~; and p = 0.

Claim 14 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein M^1 is ~~represents~~ CH_2, CO, CH_2CH_2 or CH_2CO; M^2 is ~~represents~~ NR^{12} in which R^{12} is as defined in claim 1; M^3 is ~~represents~~ CH_2, CH_2CH_2 or propyl; $M^{3'}$ is ~~represents~~ CH_2, ethyl, propyl, isopropyl or is absent; M^4 is ~~represents~~ SOR^{13}, SO_2R^{13}, $NR^{12}SO_2R^{13}$, $SO_2NR^{14}R^{15}$, CO_2R^{13} or $CONR^{14}R^{15}$ in which R^{12} and R^{13} are defined in claim 1 and R^{14} and R^{15} each independently are ~~represent~~ H or C_{1-4} alkyl; M^5 is ~~represents~~ a group $NR^{14}R^{15}$ in which R^{14} and R^{15} together with the nitrogen atom to which they are attached is ~~represent~~ a 6-membered ring optionally containing an additional heteroatom selected from N or O, in which ring any nitrogen atom present is ~~may~~ optionally ~~be~~ substituted with a C_{1-4} alkyl group; or M^5 is ~~represents~~ a group



in which t is ~~represents~~ 2 or 3 and R^{16} is ~~represents~~ OH, NH_2, $N(C_{1-4}$ alkyl$)_2$ or OC_{1-4} alkyl; ~~more preferably R^{16} represents NH_2 or $N(CH_3)_2$;~~ or M^5 is ~~represents~~ a group $NR^{14}R^{15}$ in which R^{14} and R^{15} each independently are ~~represent~~ hydrogen or C_{1-4} alkyl, ~~more preferably hydrogen, methyl, ethyl or isopropyl~~; and M^6 is ~~represents~~ a group $NR^{14}R^{15}$ in which R^{14} and R^{15} each independently is ~~represents~~ C_{1-4} alkyl, ~~more preferably methyl,~~ or R^{14} and R^{15} together with the nitrogen atom to which they are attached is ~~represent~~ a 5- or 6-membered ring optionally containing an additional heteroatom selected from N or O, in which ring any nitrogen atom present is ~~may~~ optionally ~~be~~ substituted with a C_{1-4} alkyl group, ~~preferably a methyl group~~; or M^6 is ~~represents~~ a 5- or 6-membered heterocyclic ring system containing 1 or 2 heteroatoms selected from N or O.

Claim 15 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein M^2-M^3-M^4 is ~~represents~~ a methylsulphonylethylamino, methylsulphinylethylamino, methylsulphonylethyl(methylamino), methylsulphinylethyl(methylamino), methylsulphonylpropylamino, methylsulphinylpropylamino,

methylsulphonamidoethylamino, aminosulphonylethylamino, methylaminosulphonylethylamino, sarcosinamide, glycine, glycinamide, glycine methyl ester or acetylaminoethylamino group.

Claim 16 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein R^1 is selected from the group consisting of ~~comprising~~ furan, dihydrofuran, thiophene, imidazole, tetrazole, triazole, pyridine, pyrrole, pyrimidine, isoxazole and ~~or~~ oxadiazole.

Claim 17 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein R^1 is selected from the group consisting of ~~comprising~~ furan, imidazole, oxadiazole ~~(particularly 1,3,4 oxadiazole and 1,2,4 oxadiazole)~~ and triazole ~~(particularly 1,2,3 triazole and 1,3,4 triazole)~~.

Claim 18 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein R^6 is benzyl, fluorobenzyl, difluorobenzyl, benzyloxy, fluorobenzyloxy, pyridylmethyl, phenyl, benzenesulphonyl, phenoxy or fluorophenoxy.

Claim 19 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein U is ~~represents~~ an phenyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group.

Claim 20 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein U is ~~represents~~ a phenyl or 1H-indazolyl group.

Claim 21 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein the optional substituents for the carbocyclic or heterocyclic moiety ~~and also for other optionally substituted groups~~ include hydroxy, halogen, trifluoromethyl, trifluoromethoxy, nitro, amino, cyano, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkyl carbonyl, carboxylate and C_{1-4} alkoxy carboxyl.

Claim 22 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein X is ~~represents~~ N; Y is ~~represents~~ NR^a, wherein R^a is hydrogen or C_{1-4} alkyl; R^1 is

~~represents~~ furan, thiophene, pyrrole, pyridine, pyrimidine, pyrazine, imidazole, oxazole, isoxazole, oxadiazole, tetrazole, triazole, dioxolane or a partially or fully hydrogenated derivative of any of these groups, optionally substituted by one or more R^3 groups selected from halo, trifluoromethyl, C_{1-4} alkyl, carboxy, C_{1-4}-alkoxycarbonyl, formyl, hydroxy-C_{1-4} alkyl, 1,3-dioxolan-2-yl, amino, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, hydroxy-C_{1-4}alkanoyl-(C_{1-4}alkyl)-amino, C_{1-4} alkylamino-C_{1-4} alkyl or di(C_{1-4} alkyl)amino-C_{1-4} alkyl; p is 0; R^2 is ~~represents~~ hydrogen; R^4 is ~~represents~~ hydrogen, halo or methyl; U is ~~represents~~ phenyl, indolyl, benzimidazolyl or indazolyl, more preferably phenyl or indazolyl; and R^6 is ~~represents~~ phenyl, benzyl, α-methylbenzyl, fluorobenzyl, difluorobenzyl, pyridylmethyl, benzenesulphonyl, phenoxy, fluorophenoxy, benzyloxy or fluorobenzyloxy.

Claim 23 (Currently Amended): The ~~A~~ method as claimed in claim 1, wherein X is ~~represents~~ N; Y is ~~represents~~ NR^a, wherein R^a is hydrogen or C_{1-4} alkyl; R^1 is selected from the group consisting of ~~represents~~ a furan, dihydrofuran, thiophene, pyridine, pyrrole, pyrimidine, isoxazole, triazole, tetrazole, imidazole and ~~or~~ oxadiazole ring, ~~preferably furan, imidazole, oxadiazole and triazole,~~ substituted with an R^3 group selected from the group consisting of C_{1-4}alkyl, C_{1-4}alkylamino-C_{1-4}alkyl, di(C_{1-4}alkyl)amino-C_{1-4} alkyl, formyl, carboxy, C_{1-4}alkoxycarbonyl, dioxolanyl, trifluoromethyl, methylsulphonylethylaminomethyl, methylsulphonylethylamino-carbonyl, methylsulphonylethyl(methylamino)-methyl, methylsulphonamidoethylamino-methyl, aminosulphonylethylamino-methyl, methylaminosulphonylethylamino-methyl, N,N-dimethylaminoprop-2-ylaminomethyl, N-(2-dimethylaminoethyl)-N-ethylaminomethyl, pyridylaminomethyl, tetrahydrofuranomethylaminomethyl, piperazinylmethyl, methylpiperazinylmethyl, piperidinylmethyl, pyridylmethyl, N-(prolinamido)methyl and ~~or~~ (N,N-dimethyl-prolinamido)methyl; p is 0; R^2 is ~~represents~~ hydrogen; R^4 is ~~represents~~ hydrogen or halo; U is ~~represents~~ phenyl or indazolyl; and R^6 is selected from the group consisting of ~~represents~~ benzyl, fluorobenzyl, difluorobenzyl, pyridylmethyl, benzenesulphonyl, phenoxy, benzyloxy or fluorobenzyloxy.